Literature DB >> 20088569

Inactivation of Lactobacillus leichmannii ribonucleotide reductase by 2',2'-difluoro-2'-deoxycytidine 5'-triphosphate: covalent modification.

Gregory J S Lohman1, Joanne Stubbe.   

Abstract

Ribonucleotide reductase (RNR) from Lactobacillus leichmannii, a 76 kDa monomer using adenosylcobalamin (AdoCbl) as a cofactor, catalyzes the conversion of nucleoside triphosphates to deoxynucleotides and is rapidly (<30 s) inactivated by 1 equiv of 2',2'-difluoro-2'-deoxycytidine 5'-triphosphate (F(2)CTP). [1'-(3)H]- and [5-(3)H]F(2)CTP were synthesized and used independently to inactivate RNR. Sephadex G-50 chromatography of the inactivation mixture revealed that 0.47 equiv of a sugar was covalently bound to RNR and that 0.71 equiv of cytosine was released. Alternatively, analysis of the inactivated RNR by SDS-PAGE without boiling resulted in 33% of RNR migrating as a 110 kDa protein. Inactivation of RNR with a mixture of [1'-(3)H]F(2)CTP and [1'-(2)H]F(2)CTP followed by reduction with NaBH(4), alkylation with iodoacetamide, trypsin digestion, and HPLC separation of the resulting peptides allowed isolation and identification by MALDI-TOF mass spectrometry (MS) of a (3)H/(2)H-labeled peptide containing C(731) and C(736) from the C-terminus of RNR accounting for 10% of the labeled protein. The MS analysis also revealed that the two cysteines were cross-linked to a furanone species derived from the sugar of F(2)CTP. Incubation of [1'-(3)H]F(2)CTP with C119S-RNR resulted in 0.3 equiv of sugar being covalently bound to the protein, and incubation with NaBH(4) subsequent to inactivation resulted in trapping of 2'-fluoro-2'-deoxycytidine. These studies and the ones in the preceding paper (DOI: 10.1021/bi9021318 ) allow proposal of a mechanism of inactivation of RNR by F(2)CTP involving multiple reaction pathways. The proposed mechanisms share many common features with F(2)CDP inactivation of the class I RNRs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20088569      PMCID: PMC2855214          DOI: 10.1021/bi902132u

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  38 in total

1.  The structure of Escherichia coli cytosine deaminase.

Authors:  Gregory C Ireton; Gerry McDermott; Margaret E Black; Barry L Stoddard
Journal:  J Mol Biol       Date:  2002-01-25       Impact factor: 5.469

Review 2.  The role of gemcitabine alone and in combination in the treatment of pancreatic cancer.

Authors:  H Oettle; D Arnold; C Hempel; H Riess
Journal:  Anticancer Drugs       Date:  2000-11       Impact factor: 2.248

Review 3.  Gemcitabine in hematologic malignancies.

Authors:  C Nabhan; N Krett; V Gandhi; S Rosen
Journal:  Curr Opin Oncol       Date:  2001-11       Impact factor: 3.645

Review 4.  Lung cancer: a review.

Authors:  Robert J Cersosimo
Journal:  Am J Health Syst Pharm       Date:  2002-04-01       Impact factor: 2.637

5.  Inactivation of Lactobacillus leichmannii ribonucleotide reductase by 2',2'-difluoro-2'-deoxycytidine 5'-triphosphate: adenosylcobalamin destruction and formation of a nucleotide-based radical.

Authors:  Gregory J S Lohman; Gary J Gerfen; Joanne Stubbe
Journal:  Biochemistry       Date:  2010-02-23       Impact factor: 3.162

6.  Mechanism of inactivation of human ribonucleotide reductase with p53R2 by gemcitabine 5'-diphosphate.

Authors:  Jun Wang; Gregory J S Lohman; JoAnne Stubbe
Journal:  Biochemistry       Date:  2009-12-15       Impact factor: 3.162

Review 7.  Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors.

Authors:  Romano Danesi; Giuseppe Altavilla; Elisa Giovannetti; Raffael Rosell
Journal:  Pharmacogenomics       Date:  2009-01       Impact factor: 2.533

Review 8.  Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.

Authors:  Fernando Rivera; Sara López-Tarruella; Ma Eugenia Vega-Villegas; Matilde Salcedo
Journal:  Cancer Treat Rev       Date:  2009-01-07       Impact factor: 12.111

Review 9.  Antitumor activity of sugar-modified cytosine nucleosides.

Authors:  Akira Matsuda; Takuma Sasaki
Journal:  Cancer Sci       Date:  2004-02       Impact factor: 6.716

Review 10.  Current approaches to novel therapeutics in pancreatic cancer.

Authors:  Corina E Akerele; Irina Rybalova; Howard L Kaufman; Sridhar Mani
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

View more
  7 in total

1.  Clofarabine 5'-di and -triphosphates inhibit human ribonucleotide reductase by altering the quaternary structure of its large subunit.

Authors:  Yimon Aye; Joanne Stubbe
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-31       Impact factor: 11.205

Review 2.  Molybdopterin biosynthesis-Mechanistic studies on a novel MoaA catalyzed insertion of a purine carbon into the ribose of GTP.

Authors:  Angad P Mehta; Sameh H Abdelwahed; Tadhg P Begley
Journal:  Biochim Biophys Acta       Date:  2015-04-17

3.  Genetic characterization and role in virulence of the ribonucleotide reductases of Streptococcus sanguinis.

Authors:  DeLacy V Rhodes; Katie E Crump; Olga Makhlynets; Melanie Snyder; Xiuchun Ge; Ping Xu; JoAnne Stubbe; Todd Kitten
Journal:  J Biol Chem       Date:  2013-12-31       Impact factor: 5.157

4.  Modulation of the ribonucleotide reductase M1-gemcitabine interaction in vivo by N-ethylmaleimide.

Authors:  Zhengming Chen; Jun Zhou; Yingtao Zhang; Gerold Bepler
Journal:  Biochem Biophys Res Commun       Date:  2011-08-27       Impact factor: 3.575

5.  One-electron oxidation of gemcitabine and analogs: mechanism of formation of C3' and C2' sugar radicals.

Authors:  Amitava Adhikary; Anil Kumar; Ramanjaneyulu Rayala; Ragda M Hindi; Ananya Adhikary; Stanislaw F Wnuk; Michael D Sevilla
Journal:  J Am Chem Soc       Date:  2014-10-23       Impact factor: 15.419

6.  SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.

Authors:  A Khatri; B W Williams; J Fisher; R C Brundage; V J Gurvich; L G Lis; K M Skubitz; A Z Dudek; E W Greeno; R A Kratzke; J K Lamba; M N Kirstein
Journal:  Br J Cancer       Date:  2013-12-03       Impact factor: 7.640

7.  Model Substrate/Inactivation Reactions for MoaA and Ribonucleotide Reductases: Loss of Bromo, Chloro, or Tosylate Groups from C2 of 1,5-Dideoxyhomoribofuranoses upon Generation of an α-Oxy Radical at C3.

Authors:  Stanislaw F Wnuk; Mukesh M Mudgal; Ireneusz Nowak; Morris J Robins
Journal:  Molecules       Date:  2020-05-29       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.